Phase II study of a combination of cisplatin, all- Trans- retinoic acid and interferon-α in squamous cell carcinoma: Clinical results and Pharmacokinetics

Anticancer Research

Volumn 21, Issue 2 B, 2001, Pages 1431-1437

  Goncalves, A ^a   Camerlo, J ^a   Bun, H ^a   Gravis, G ^a   Genre, D ^a   Bertucci, F ^a   Resbeut, M ^a   Pech Gourg, F ^a   Durand, A ^a   Maraninchi, D ^a   Viens, P ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

All trans retinoic acid; Cisplatin; Interferon ; Squamous cell carcinoma

Indexed keywords

CISPLATIN; CYTOKINE; CYTOTOXIC AGENT; RECOMBINANT ALPHA2A INTERFERON; RETINOIC ACID;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERON-ALPHA; LUNG NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRETINOIN; UTERINE CERVICAL NEOPLASMS;

EID: 0035013493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Overview of combined modality therapies for head and neck cancer
2. Chemotherapy of advanced and recurrent cervical carcinoma
3. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer
4. Retinoids in cancer prevention and therapy
5. Cancer chemoprevention
6. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck
7. 13-cis-retinoic acid in the treatment of oral leukoplakia
8. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
9. All-trans-retinoic acid in acute promyelocytic leukemia
10. The alpha interferons: Clinical overview
11. Antiproliferative and synergistic effect of interferon alpha-2a, retinoids and their association in established human cancer cell lines
12. Retinoic acid and interferon combination studies in human cancer
13. 13-cis-retinoic acid plus interferon alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix
14. 13-cis-retinoic acid and interferon alpha-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin
15. 13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix
16. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
17. Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in hunan ovarian carcinoma cell lines
18. Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic-acid-induced cellular differentiation of a murine embryonal carcinoma cell line
19. Enhanced antitwnor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice
20. All-trans-retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells
21. Clinical pharmacology of oral all-frans retinoic acid in patients with acute promyelocytic leukemia
22. Phase I and pharmakokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer
23. Simultaneous determination of all-trans-, 13-cis-, 9-cis-retinoic acid and their 4-oxo-metabolites in plasma by high-performance liquid chromatography
24. 13-cis-retinoic acid plus interferon-alpha: A phase II clinical study in squamous cell carcinoma of the lung and the head and neck
25. Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma
26. 13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: A Southwest Oncology Group phase II randomized trial
27. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi's sarcoma
28. All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: Clinical and pharmacokinetic studies
29. Phase II study of interferon-alpha and all-trans-retinoic acid in metastatic renal cell carcinoma
30. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: An Eastern Cooperative Oncology Group Study
31. Phase II study of a combination of low-dose cisplatin with 13-cis-retinoic acid and interferon-alpha in patients with advanced head and neck squamous cell carcinoma
32. Metabolism of All-transretinoic acid in hamster liver microsomes: Oxidation of 4-hydroxy- to 4-keto-retinoic acid
33. Depression of hepatic cytochrome P-450-dependent monooxygenase systems with administered interferon inducing agents
34. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and - causes growth inhibition in xenografts in vivo
35. A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice
36. Chemoprevention of mammary, carcinoma by LGD1069 (Targretin): An RXR-selective ligand
37. Initial clinical trial of a selective retinoid x receptor ligand, LGD1069
38. A Phase I study of LGD1069 in adults with advanced cancer